Thursday, February, 27, 2020 12:07:16

SELLAS enrolls first patient in Phase 1 study of GPS for treating MPM

SELLAS Life Sciences Group Inc., a biopharmaceutical firm that innovates novel cancer immunotherapies, has recently revealed the enrollment of initial patient in investigator-sponsored clinical study of GPS (Galinpepimut-S), its WT1 (Wilms tumor-1)-targeting peptide immunotherapeutic agent, in combination with nivolumab (Opdivo®), for patients suffering from MPM …